NYSE:NUVB

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio Inc. has quietly morphed from an obscure penny stock into one of 2025’s wildest oncology stories. As of December 11, 2025, the stock is trading in the high single digits, up roughly 200% year‑to‑date, following a string of clinical wins, a first drug approval, and a wave of fresh analyst upgrades. TipRanks+1

11 December 2025

NYSE:NUVB

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025

NEW YORK, November 19, 2025 – Shares of Nuvation Bio Inc. exploded higher on Wednesday after B. Riley Securities initiated coverage with a bullish rating and a $12 price target, adding fresh fuel to a rally driven by the successful launch of the company’s lung cancer drug IBTROZI™ and a blockbuster third quarter. Investing.com+2Parameter+2

19 November 2025

Biotechnology·NYSE:NUVB·Stock Market

NYSE:NUVB 19 November 2025 - 11 December 2025

Nuvation Bio (NUVB) Soars After $18 Price-Target Hike – Is This High‑Growth Cancer Stock Still a Buy in 2025?

Nuvation Bio (NUVB) Stock Soars ~50% Today as B. Riley Starts Coverage With $12 Target – 19 November 2025